Phaseline

Companies › Zhejiang Hisun Pharmaceutical

Zhejiang Hisun Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AST-3424
AKR1C3 inhibitor
AKR1C3Phase 2HCC - Hepatocellular CarcinomaOct 2027
HS387–Phase 1Advanced Solid CancersJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07310173AST-3424Phase 2HCC - Hepatocellular CarcinomaOncologyOct 2027
NCT07092748HS387Phase 1Advanced Solid CancersOncologyJun 2028

Targets

AKR1C3 (1)

Companies with the same targets

–

Companies built like this

Tianjin ConjuStar Biologics HitGen Shenzhen TargetRx Clarity Pharmaceuticals TYK Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.